CF Pharmtech, Inc.

CF Pharmtech, Inc. is a pharmaceutical company specializing in the research, development, manufacturing, and commercialization of complex inhalation formulations and drug delivery technologies. The company operates through integrated platforms covering complex formulations, innovative drugs, medical devices, and technical services including contract development and manufacturing organization (CDMO) and contract manufacturing organization (CMO) capabilities. Its main products include inhalation solutions, nebulization solutions, nasal sprays, and dry powder inhalers, with key brands such as Changqi (budesonide suspension for inhalation) and Changshu (salbutamol sulfate solution). The company serves patients with respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD), bronchiectasis, pulmonary fibrosis, and pulmonary arterial hypertension, as well as nasal conditions like allergic rhinitis and chronic rhinosinusitis. It also explores central nervous system disorders via the nose-to-brain pathway. CF Pharmtech serves markets in China, the United States, Europe, and Southeast Asia, partnering with entities such as Jointown Quanqing Health, Akang Health, and JD Health for chronic disease management. The company was founded in 2007. Notable pipeline assets include CF017, CF018, ICF001, ICF004, and siRNA nucleic acid delivery platforms. Subsidiaries include CF PharmTech Jiangsu Limited, Suzhou CF Health Technology Co., Ltd., CF PharmTech Wuxi Limited, Suzhou Wusheng Technology Co., Ltd., Guangzhou CF, and CF PHARMTECH HONGKONG LIMITED.